Akums Drugs Receives Voluntary ESG Rating of 65 for FY26 from NSE Sustainability
Akums Drugs and Pharmaceuticals Ltd 路 Others (Uncategorized) 路 03 Sept 2026, 8:32 pm
Akums Drugs Receives Voluntary ESG Rating of 65 for FY26 from NSE Sustainability On 2nd Sep'26, Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY26 from NSE Sustainability Ratings & Analytics Limited. The rating was voluntarily assigned by the agency based solely on publicly available information, as the company did not officially engage NSE Sustainability for this evaluation. This independent ESG assessment provides market participants with a benchmark for the company's environmental, social, and governance practices without active management solicitation.
Original exchange filing (PDF)
More announcements from Akums Drugs and Pharmaceuticals Ltd
- Intimation of Schedule of the Investors/Analysts Meet 路 10 Nov 2026
- Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026 路 05 Nov 2026
- Audio recording of Earning/ Quarterly Conference Call 路 03 Nov 2026
- Newspaper Publication 路 03 Nov 2026
- Final Report of CRISIL Ratings Limited, Monitoring Agency 路 03 Nov 2026
- Q2 FY 2026-27 - Investor Presentation 路 02 Nov 2026
- Press Release 路 02 Nov 2026
- Mr. Sanjay Kumar has been designated as Senior Management Personnel of the Company. 路 02 Nov 2026
